- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- May 2024
- 165 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- July 2022
- 193 Pages
Global
From €5229EUR$5,500USD£4,393GBP
- Report
- August 2022
Global
From €751EUR$790USD£631GBP
- Report
- January 2022
- 60 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- May 2023
- 160 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- February 2024
- 75 Pages
Global
From €3323EUR$3,495USD£2,791GBP
- Report
- December 2022
- 69 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Book
- November 2020
- 464 Pages
Female Sexual Dysfunction (FSD) is a medical condition that affects a woman's sexual desire, arousal, orgasm, and satisfaction. It is a complex condition that can be caused by physical, psychological, and social factors. FSD is a growing area of research and treatment within Women's Health, as it is estimated that up to 40% of women experience some form of FSD.
FSD is often treated with a combination of lifestyle changes, medications, and psychotherapy. Lifestyle changes may include stress management, exercise, and dietary changes. Medications may include hormonal treatments, antidepressants, and other medications. Psychotherapy may include cognitive-behavioral therapy, sex therapy, and couples counseling.
There are a number of companies in the Female Sexual Dysfunction market, including Sprout Pharmaceuticals, Palatin Technologies, and Apricus Biosciences. These companies are focused on developing treatments for FSD, such as hormonal treatments, medications, and other therapies. Show Less Read more